|
This time-release niacin is a unique wax-matrix sustained-release tablet which allows for maximal benefit with the least side-effects.
Niacin Metabolism:
Niacin is metabolized by two pathways (see figure below), Niacin can be conjugated with glycine-resulting in Nicotinuric
Acid (NUA)- resulting in most of the benefits of niacin but also the flushing side-effects. Niacin can also be converted to
Niacinamide (NAM) and other metabolites which are harmless at lower levels but can be potentially hepatotoxic at doses
exceeding 1.5 grams per day.
The goal of a sustained-release niacin product is to release as much niacin via the first pathway (NUA) without causing flushing, while fully releasing all the niacin before the secondary pathway is able to ofrm potentially hepatotoxic metabolites.
Research Findings †:
The use of niacin for managing lipid markers for cardiovascular disease is well established.
- Reducing LDL and Total Cholesterol (5-25%)
- Increasing HDL Cholesterol (15-35%)
- Decreasing Triglycerides (20-50%)
- Increase in ApoA Lipoproteins
- Decrease In ApoB Lipoproteins
- Shift to larger (less atherogenic) LDL particles
- Reduction in Lp(a)
†These numbers and statements represent typical ranges reported in the literature using various forms of time-release niacin (including this wax-matrix form) and should not be construed as a specific claim for this product. Please see references below for specific details.
Dose:
1000-1500 mg (2-3 tablets) per day in divided doses (with meals)
Contraindication, adverse Reactions:
Flushing occurs in 3-12% of subject and is dose dependent. Smaller initial doses and avoidance of hot drinks after niacin
Ingestion can help reduce this effect. Liver enzymes should be monitored, especially in patients using 1500 mg or more per day. Certain diabetic and metabolic syndrome patients may see a change in fasting blood sugar with the use of niacin.
Supplement Facts |
| Serving Size: 1 Tablet |
| Servings Per Container: 90 |
| 1 Tablet contains |
Amount Per Serving |
%DV |
| Time Release contains (Niamax™) |
500 |
2500% |
| * % Daily Value not established |
| Dose Form: Tablet 7/16" scored |
| Other Ingredients: Vegetable Stearine, Carnauba Wax, Magnesium Stearate (Veg) and Silica. |
References:
1. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004 Apr 12;164(7):697-705.
2. Morgan JM, Carey CM, Lincoff A, Capuzzi DM. The effects of niacin on lipoprotein subclass distribution. Prev Cardiol. 2004; 7(4);182-7.
3. Morgan JM, Capuzzi DM et al. Effects of extended-release niacin on lipoprotein subclass distributin. Am J Cardiol. 2003 Jun 15;9(12);1432-6.
4. Canner PL, Furberg CD, Terrin ML, McGovern ME, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project), Am J Cardiol. 2005;95(2)-254-7.
5. Keenan JM, Bae CY et al. Treatment of hypercholesterolemia; comparison of younger versus older patients using wax-matrix sustained-release niacin. J Am Geriatr Soc. 1992; 40(1);12-8.
6. Keenan JM, Fontaine PL et al. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991 Jul;151(7);1424-32.
|
